To test these hypotheses, we compared the risk of all-cause mortality and new MACE (including cardiovascular mortality, myocardial infarction, and ischemic stroke) in adults with IMIDs and type 2 diabetes initiating a GLP-1-RA versus a DPP-4i, and then repeated this analysis in age- and sex-matched adults without IMIDs to compare the effect sizes. Here, GLP1R is linked to myocardial infarction.